POS-311 POLYPHARMACY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HIGH PROGRESSION RISK
Main Authors: | L. CHENG, S. Badve, on behalf of the CKD-FIX Study Investigators, L |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024921004733 |
Similar Items
-
Polypharmacy and the Progression of Chronic Kidney Disease: Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease
by: Hyang Ki Min, et al.
Published: (2021-06-01) -
POS-333 THE INDIAN CHRONIC KIDNEY DISEASE STUDY: DETAILED DESCRIPTION OF BASELINE CHARACTERISTICS
by: V. Kumar, et al.
Published: (2021-04-01) -
Pharmacist-Led Collaborative Medication Management for the Elderly with Chronic Kidney Disease and Polypharmacy
by: A Jeong Kim, et al.
Published: (2021-04-01) -
The burden of polypharmacy and pattern of comorbidities among chronic kidney disease patients in clinical practice
by: Olumuyiwa John Fasipe, et al.
Published: (2018-01-01) -
Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients
by: Shuo-Chun Weng, et al.
Published: (2016-12-01)